Last updated: October 3, 2024
Sponsor: Mansoura University Hospital
Overall Status: Active - Recruiting
Phase
N/A
Condition
Emphysema
Treatment
Nano-silver nitrate
Silver Nitrate
Bronchoscopic lung volume reduction
Clinical Study ID
NCT06629558
R.24.09.2776
Ages 40-75 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- COPD of grade III and IV according to GOLD 2024 staging of COPD with localized (heterogeneous) emphysema as determined by high resolution computerized tomography (HRCT) of the chest with area of destruction >-950 Hounsfield units (HU) andrespiratory symptoms despite optimal medical therapy with the following criteria:Patient less than 75 years of age not candidate for or had refused lung volumereduction surgery but fit for fibro-optic bronchoscope (FOB). Lung volumes criteria:FEV1 less than 60% of predicted value, Residual volume (RV) more than 100% ofpredicted value, Total lung capacity (TLC) more than 100% of predicted value, 6 MWTof less than 450 meters.
Exclusion
Exclusion Criteria:
Significant co-morbidities that limits exercise capacity or prognosis ascardiovascular diseases (heart failure, arrhythmia, ischemic heart disease) and lungcancer.
Patients unfit or refused FOB.
Homogenous emphysema.
More than 75 years of age.
Associated lung fibrosis.
FEV1 > 60%.
Current smoker.
Study Design
Total Participants: 30
Treatment Group(s): 3
Primary Treatment: Nano-silver nitrate
Phase:
Study Start date:
October 01, 2024
Estimated Completion Date:
March 01, 2025
Study Description
Connect with a study center
Mohamed AbdElmoniem
Mansoura, 35516
EgyptActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.